NASDAQ:AGIO - Agios Pharmaceuticals Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$76.56 +0.48 (+0.63 %)
(As of 08/16/2018 10:48 AM ET)
Previous Close$75.88
Today's Range$74.52 - $76.80
52-Week Range$51.62 - $99.82
Volume2,508 shs
Average Volume470,652 shs
Market Capitalization$4.43 billion
P/E Ratio-11.15
Dividend YieldN/A
Beta1.97
Agios Pharmaceuticals logoAgios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML. The company also develops Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase I clinical trial for advanced solid tumors; Phase III clinical trials for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination and Phase III clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase I clinical trial for the treatment of hematologic malignancies; and AG-348, a small molecule potent activator that is in Phase II clinical trials for the treatment of pyruvate kinase deficiency. Agios Pharmaceuticals has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts.

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AGIO
CUSIPN/A
Phone617-649-8600

Debt

Debt-to-Equity RatioN/A
Current Ratio8.88
Quick Ratio8.88

Price-To-Earnings

Trailing P/E Ratio-11.15
Forward P/E Ratio-12.74
P/E GrowthN/A

Sales & Book Value

Annual Sales$43.01 million
Price / Sales103.23
Cash FlowN/A
Price / CashN/A
Book Value$7.69 per share
Price / Book9.96

Profitability

EPS (Most Recent Fiscal Year)($6.75)
Net Income$-314,670,000.00
Net Margins-462.08%
Return on Equity-51.71%
Return on Assets-38.92%

Miscellaneous

Employees382
Outstanding Shares57,990,000
Market Cap$4.43 billion

Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals Inc (NASDAQ:AGIO) announced its quarterly earnings data on Thursday, August, 2nd. The biopharmaceutical company reported ($1.19) EPS for the quarter, topping the Zacks' consensus estimate of ($1.62) by $0.43. The biopharmaceutical company earned $40.40 million during the quarter, compared to the consensus estimate of $12.47 million. Agios Pharmaceuticals had a negative return on equity of 51.71% and a negative net margin of 462.08%. The business's revenue for the quarter was up 257.5% on a year-over-year basis. During the same period in the previous year, the company posted ($1.78) earnings per share. View Agios Pharmaceuticals' Earnings History.

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for Agios Pharmaceuticals.

What price target have analysts set for AGIO?

11 brokerages have issued 1 year target prices for Agios Pharmaceuticals' stock. Their predictions range from $83.00 to $125.00. On average, they expect Agios Pharmaceuticals' stock price to reach $99.4444 in the next twelve months. This suggests a possible upside of 29.9% from the stock's current price. View Analyst Price Targets for Agios Pharmaceuticals.

What is the consensus analysts' recommendation for Agios Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agios Pharmaceuticals.

What are Wall Street analysts saying about Agios Pharmaceuticals stock?

Here are some recent quotes from research analysts about Agios Pharmaceuticals stock:
  • 1. Needham & Company LLC analysts commented, "BeiGene announced the pricing of its Hong Kong initial public offering of 65,600,000 ordinary shares. Based on the assumed exchange rate, the public offering, priced at $13.76 (HK$108) per share or $178.9 per American Depositary Share (ADS) is expected to raise ~$903M (HK$7.08bn)." (8/2/2018)
  • 2. Canaccord Genuity analysts commented, "We eagerly await the FDA’s potential acceptance of this NDA. Ahead of a potentially important period for the company, our thesis on the stock is unchanged. Specifically, in our view: 1) lumateperone, if approved, could become a meaningful competitor in the schizophrenia space given its benign safety/tolerability profile vs. the current standard of care; 2) ITCI presents scarcity value in that it is one of the few companies with promising late-stage assets in the neuropsychiatry space, where pipeline success remains somewhat elusive." (8/2/2018)
  • 3. Cann analysts commented, "We had anticipated FDA approval of Tibsovo (ivosidenib/AG-120) in late-August 2018. With the approval being granted one month ahead of schedule, the timing is supportive of our expected Q318 launch. We continue to believe ivosidenib will be a major driver of growth and value for Agios. Pricing for the drug at approximately $26,115 per month is in line with our estimate, as is the prescribed minimum duration of use. As a result of timing and pricing, our outlook remains positive and unchanged." (7/20/2018)
  • 4. According to Zacks Investment Research, "Agios received an FDA approval of Idhifa (enasidenib) in August for treatment of AML, which was a huge boost, given the immense commercial potential in the target market. We are also optimistic about its collaboration with Celgene as it provides Agios with regular funds. The company’s progress with the pipeline candidates, AG-120 and AG-881, has been quite impressive too. In December, the company submitted a new drug application to the FDA for  AG-120 for treatment of AML. Shares of the company have outperformed the industry in the last one year. However, Agios depends heavily on partner Celgene for revenues as Idhifa is only in the early stages of launch. Also, the decision to discontinue the development of AG-519 was disappointing. Stiff competition is another matter of concern for the company." (1/16/2018)

Who are some of Agios Pharmaceuticals' key competitors?

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the folowing people:
  • Dr. David P. Schenkein, CEO, Pres & Director (Age 61)
  • Dr. Lewis Clayton Cantley, Co-Founder & Member of Scientific Advisory Board (Age 69)
  • Mr. Andrew Hirsch, Chief Financial Officer (Age 47)
  • Dr. Scott A. Biller Ph.D., Chief Scientific Officer (Age 62)
  • Dr. Christopher J. Bowden, Chief Medical Officer (Age 57)

Has Agios Pharmaceuticals been receiving favorable news coverage?

Media stories about AGIO stock have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Agios Pharmaceuticals earned a daily sentiment score of 0.03 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 47.30 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Agios Pharmaceuticals.

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (14.90%), BlackRock Inc. (5.60%), BB Biotech AG (3.79%), First Trust Advisors LP (1.27%), Baillie Gifford & Co. (1.09%) and Partner Fund Management L.P. (1.06%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Celgene European Investment Co, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, David Scadden, Kaye I Foster-Cheek, Lewis Clayton Jr Cantley, Robert Nelsen, Scott Biller and Steven L Hoerter. View Institutional Ownership Trends for Agios Pharmaceuticals.

Which major investors are selling Agios Pharmaceuticals stock?

AGIO stock was sold by a variety of institutional investors in the last quarter, including BB Biotech AG, Point72 Asset Management L.P., Frontier Capital Management Co. LLC, Partner Fund Management L.P., Bank of America Corp DE, Federated Investors Inc. PA, Alps Advisors Inc. and Alps Advisors Inc.. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, David P Schenkein, Kaye I Foster-Cheek, Lewis Clayton Jr Cantley, Scott Biller and Steven L Hoerter. View Insider Buying and Selling for Agios Pharmaceuticals.

Which major investors are buying Agios Pharmaceuticals stock?

AGIO stock was purchased by a variety of institutional investors in the last quarter, including Woodford Investment Management Ltd, Wells Fargo & Company MN, Castleark Management LLC, First Trust Advisors LP, Handelsbanken Fonder AB, Baillie Gifford & Co., BlackRock Inc. and FMR LLC. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Celgene European Investment Co, Corp /De/ Celgene and David Scadden. View Insider Buying and Selling for Agios Pharmaceuticals.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $76.56.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $4.43 billion and generates $43.01 million in revenue each year. The biopharmaceutical company earns $-314,670,000.00 in net income (profit) each year or ($6.75) on an earnings per share basis. Agios Pharmaceuticals employs 382 workers across the globe.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]


MarketBeat Community Rating for Agios Pharmaceuticals (NASDAQ AGIO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  308 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  572
MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe AGIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.